Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).
This is a Phase IV, single-arm, prospective, open-label, multicenter, interventional study to evaluate safety and efficacy of regorafenib in patients with mCRC who have been previously treated with fluoropyrimidine , oxaliplatin-, and irinotecan based chemotherapy, an anti-VEGF therapy, and, if RAS wild type, an anti-EGFR therapy.
Metastatic Colorectal Cancer
DRUG: Regorafenib (Stivarga, BAY73-4506)
Number of Adverse Events, From the start of regorafenib treatment up to 30 days after the last dose of regorafenib|Changes in Eastern Cooperative Oncology Group Performance Status (ECOG PS), From the start of regorafenib treatment up to 30 days after the last dose of regorafenib|Percentage of participants with change in worst grades for hematological and biochemical toxicities according to CTCAE version 4.03, based on laboratory measurements, From the start of regorafenib treatment up to 30 days after the last dose of regorafenib|Change in Body weight (kg), From the start of regorafenib treatment up to 30 days after the last dose of regorafenib|Change in Body height (cm), From the start of regorafenib treatment up to 30 days after the last dose of regorafenib|Change in Systolic / Diastolic BP (mmHg), From the start of regorafenib treatment up to 30 days after the last dose of regorafenib|Change in heart rate (beats/min), From the start of regorafenib treatment up to 30 days after the last dose of regorafenib
Disease control rate (DCR), Defined as proportion of patients achieving complete response (CR), partial response (PR), or SD (stable disease) per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1, In each participant, every 8 weeks from the start of regorafenib until radiological disease progression, lost to follow-up, consent withdrawn or end of study, whichever occurs first|Overall response rate (ORR), Defined as proportion of patients achieving CR, and PR per RECIST v.1.1, In each participant, every 8 weeks from the start of regorafenib until radiological disease progression, lost to follow-up, consent withdrawn or end of study, whichever occurs first|Progression free survival (PFS), Progression free survival is defined as the time from study drug assignment to progressive disease (PD) or death from any cause or date of last tumor assessment if the patient did not progress or die., In each participant, every 8 weeks from the start of regorafenib until radiological disease progression, lost to follow-up, consent withdrawn or end of study, whichever occurs first|Overall survival (OS), Overall survival is defined as the time from study drug assignment to death from any cause or last date when the patient was known to be alive., In each participant, every 8 weeks from the start of regorafenib until death, lost to follow-up, consent withdrawn or end of study, whichever occurs first
This is a Phase IV, single-arm, prospective, open-label, multicenter, interventional study to evaluate safety and efficacy of regorafenib in patients with mCRC who have been previously treated with fluoropyrimidine , oxaliplatin-, and irinotecan based chemotherapy, an anti-VEGF therapy, and, if RAS wild type, an anti-EGFR therapy.